CC16: A Biomarker of Pollutant Exposure and Future Lung Disease?

Abstract

1. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med 2005;352: 1992–2001. 2. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003;168:918–951. 3. Breuer O, Schultz A, Turkovic L, de Klerk N, Keil AD, Brennan S, et al. Changing prevalence of lower airway infections in young children with cystic fibrosis. Am J Respir Crit Care Med 2019;200:590–599. 4. Hoch H, Sontag MK, Scarbro S, Juarez-Colunga E, McLean C, Kempe A, et al. Clinical outcomes in U.S. infants with cystic fibrosis from 2001 to 2012. Pediatr Pulmonol 2018;53:1492–1497. 5. Möller LV, Regelink AG, Grasselier H, van Alphen L, Dankert J. Antimicrobial susceptibility of Haemophilus influenzae in the respiratory tracts of patients with cystic fibrosis. Antimicrob Agents Chemother 1998;42:319–324. 6. Hurley MN, Fogarty A, McKeever TM, Goss CH, Rosenfeld M, Smyth AR. Early respiratory bacterial detection and antistaphylococcal antibiotic prophylaxis in young children with cystic fibrosis. Ann Am Thorac Soc 2018;15:42–48. 7. Heltshe SL, Mayer-Hamblett N, Burns JL, Khan U, Baines A, Ramsey BW, et al.; GOAL (the G551D Observation-AL) Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network. Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor. Clin Infect Dis 2015;60:703–712. 8. Hisert KB, Heltshe SL, Pope C, Jorth P, Wu X, Edwards RM, et al. Restoring cystic fibrosis transmembrane conductance regulator function reduces airway bacteria and inflammation in people with cystic fibrosis and chronic lung infections. Am J Respir Crit Care Med 2017;195:1617–1628. 9. Hubert D, Dehillotte C, Munck A, David V, Baek J, Mely L, et al. Retrospective observational study of French patients with cystic fibrosis and a Gly551Asp-CFTR mutation after 1 and 2years of treatment with ivacaftor in a real-world setting. J Cyst Fibros 2018;17: 89–95. 10. Two phase 3 studies of the triple combination of VX-659, tezacaftor and ivacaftor met primary endpoint of improvement in lung function (ppFEV1) in people with cystic fibrosis [press release]. Boston, MA: Vertex Pharmaceuticals; November 27, 2018. 11. Saunders RV, Modha DE, Claydon A, Gaillard EA. Chronic Aspergillus fumigatus colonization of the pediatric cystic fibrosis airway is common and may be associated with a more rapid decline in lung function. Med Mycol 2016;54:537–543. 12. Wainwright CE, Vidmar S, Armstrong DS, Byrnes CA, Carlin JB, Cheney J, et al.; ACFBAL Study Investigators. Effect of bronchoalveolar lavage-directed therapy on Pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis: a randomized trial. JAMA 2011;306:163–171. 13. Tracy MC, Moss RB. The myriad challenges of respiratory fungal infection in cystic fibrosis. Pediatr Pulmonol 2018;53: S75–S85. 14. Jubin V, Ranque S, Stremler Le Bel N, Sarles J, Dubus JC. Risk factors for Aspergillus colonization and allergic bronchopulmonary aspergillosis in children with cystic fibrosis. Pediatr Pulmonol 2010; 45:764–771. 15. Hong G, Psoter KJ, Jennings MT, Merlo CA, Boyle MP, Hadjiliadis D, et al. Risk factors for persistent Aspergillus respiratory isolation in cystic fibrosis. J Cyst Fibros 2018;17:624–630.